<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is the commonest <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> worldwide and is a growing problem </plain></SENT>
<SENT sid="1" pm="."><plain>AF is responsible for 25% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001297'>strokes</z:hpo>, and these patients suffer greater mortality and disability </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> has traditionally been the only successful therapy for <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention, but its limitations have resulted in underutilisation </plain></SENT>
<SENT sid="3" pm="."><plain>Major progress has been made in AF research, leading to improved management strategies </plain></SENT>
<SENT sid="4" pm="."><plain>Better risk stratification permits identification of truly low-risk patients who do not require anticoagulation and we are able to simplify ourevaluation of a patient's <z:mp ids='MP_0001914'>bleeding</z:mp> risk.The advent of novel <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> means <z:chebi fb="8" ids="10033">warfarin</z:chebi> is no longer the only choice for <z:hpo ids='HP_0001297'>stroke</z:hpo> prophylaxis </plain></SENT>
<SENT sid="5" pm="."><plain>These drugs circumvent many of <z:chebi fb="8" ids="10033">warfarin</z:chebi>'s inconveniences, but onlylong-term study and use will conclusively demonstrate how they compare to <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>The landscape of <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention in AF has changed with effective alternatives to <z:chebi fb="8" ids="10033">warfarin</z:chebi> available for the first time in 60 years-but each new option brings new considerations </plain></SENT>
</text></document>